South Korea's Pharmicell Expands Plant Capacity

---

Researched by Industrial Info Resources (Sugar Land, Texas)--In line with the South Korean government's move to improve the advanced regenerative medical environment, Pharmicell Company Limited (South Korea), a stem cell therapy production company, will expand by constructing its second good manufacturing practice (GMP) plant.

Located in Songnam-si, South Korea, GMP Plant 2 is designed as a "smart plant" that complies with the latest regulations, so it can be efficiently controlled in one place through a central control system. In particular, it is possible to efficiently manufacture various types of cell therapy without concerns of cross-contamination by having an individual air conditioning system in a sterile workroom.

Following the construction of GMP Plant 2, Pharmicell plans to renovate GMP Plant 1, to triple the production capacity of stem cell therapy production to prepare for the launch of alcoholic cirrhosis treatments and impotence treatments currently in their clinical phases.

Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech databases can click here for the project reports and click here for the related plant profile.

In all, Industrial Info is tracking six active cellular and gene therapy product-related projects in South Korea, worth US$191 million. Subscribers can click here for a list of detailed project reports.

Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking more than 200,000 current and future projects worth $17.8 Trillion (USD).